David L. Veenstra - Publications

Affiliations: 
Pharmacy University of Washington, Seattle, Seattle, WA 
Area:
General, Epidemiology, General Economics

165 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2020 Basit A, Prasad B, Estergreen JK, Sabath DE, Alade N, Veenstra D, Rettie AE, Thummel K. A novel LC-MS/MS assay for quantification of des-carboxy prothrombin and characterization of warfarin induced changes. Clinical and Translational Science. PMID 32004415 DOI: 10.1111/cts.12757  0.32
2019 Kim DD, Guzauskas GF, Bennette CS, Basu A, Veenstra DL, Ramsey SD, Carlson JJ. Influence of Modeling Choices on Value of Information Analysis: An Empirical Analysis from a Real-World Experiment. Pharmacoeconomics. PMID 31631254 DOI: 10.1007/s40273-019-00848-8  0.4
2019 Bounthavong M, Butler J, Dolan CM, Dunn JD, Fisher KA, Oestreicher N, Pitt B, Hauptman PJ, Veenstra DL. Correction to: Cost-Effectiveness Analysis of Patiromer and Spironolactone Therapy in Heart Failure Patients with Hyperkalemia. Pharmacoeconomics. PMID 31089966 DOI: 10.1007/s40273-019-00809-1  0.4
2019 Henderson LM, Robinson RF, Ray L, Li T, Dillard DA, Schilling BD, Mosley M, Janssen PL, Fohner AE, Rettie AE, Thummel KE, Thornton TA, Veenstra DL. VKORC1 and Novel CYP2C9 Variation Predict Warfarin Response in Alaska Native and American Indian People. Clinical and Translational Science. PMID 30821933 DOI: 10.1111/cts.12611  0.32
2018 Bounthavong M, Butler J, Dolan CM, Dunn JD, Fisher KA, Oestreicher N, Pitt B, Hauptman PJ, Veenstra DL. Cost-Effectiveness Analysis of Patiromer and Spironolactone Therapy in Heart Failure Patients with Hyperkalemia. Pharmacoeconomics. PMID 30194623 DOI: 10.1007/s40273-018-0709-3  0.4
2018 Carlson JJ, Kim DD, Guzauskas GF, Bennette CS, Veenstra DL, Basu A, Hendrix N, Hershman DL, Baker L, Ramsey SD. Integrating value of research into NCI Clinical Trials Cooperative Group research review and prioritization: A pilot study. Cancer Medicine. PMID 30030904 DOI: 10.1002/cam4.1657  0.4
2016 Serbin MA, Guzauskas GF, Veenstra DL. Clopidogrel-Proton Pump Inhibitor Drug-Drug Interaction and Risk of Adverse Clinical Outcomes Among PCI-Treated ACS Patients: A Meta-analysis. Journal of Managed Care & Specialty Pharmacy. 22: 939-47. PMID 27459657 DOI: 10.18553/jmcp.2016.22.8.939  1
2016 Green RC, Goddard KA, Jarvik GP, Amendola LM, Appelbaum PS, Berg JS, Bernhardt BA, Biesecker LG, Biswas S, Blout CL, Bowling KM, Brothers KB, Burke W, Caga-Anan CF, Chinnaiyan AM, ... ... Veenstra DL, et al. Clinical Sequencing Exploratory Research Consortium: Accelerating Evidence-Based Practice of Genomic Medicine. American Journal of Human Genetics. PMID 27181682 DOI: 10.1016/j.ajhg.2016.04.011  1
2016 Bennette CS, Veenstra DL, Basu A, Baker LH, Ramsey SD, Carlson JJ. Development and Evaluation of an Approach to Using Value of Information Analyses for Real-Time Prioritization Decisions Within SWOG, a Large Cancer Clinical Trials Cooperative Group. Medical Decision Making : An International Journal of the Society For Medical Decision Making. PMID 27012232 DOI: 10.1177/0272989X16636847  1
2016 Bennette CS, Ramsey SD, McDermott CL, Carlson JJ, Basu A, Veenstra DL. Predicting Low Accrual in the National Cancer Institute's Cooperative Group Clinical Trials. Journal of the National Cancer Institute. 108. PMID 26714555 DOI: 10.1093/jnci/djv324  1
2016 Veenstra DL. The value of routine pharmacogenomic screening - Are we there yet? A perspective on the costs and benefits of routine screening - Shouldn't everyone have this done? Clinical Pharmacology and Therapeutics. 99: 164-166. DOI: 10.1002/cpt.299  1
2015 Gallego CJ, Perez ML, Burt A, Amendola LM, Shirts BH, Pritchard CC, Hisama FM, Bennett RL, Veenstra DL, Jarvik GP. Next Generation Sequencing in the Clinic: a Patterns of Care Study in a Retrospective Cohort of Subjects Referred to a Genetic Medicine Clinic for Suspected Lynch Syndrome. Journal of Genetic Counseling. PMID 26637299 DOI: 10.1007/s10897-015-9902-0  1
2015 Basu A, Carlson JJ, Veenstra DL. A Framework for Prioritizing Research Investments in Precision Medicine. Medical Decision Making : An International Journal of the Society For Medical Decision Making. PMID 26502985 DOI: 10.1177/0272989X15610780  1
2015 Canestaro WJ, Pritchard DE, Garrison LP, Dubois R, Veenstra DL. Improving the Efficiency and Quality of the Value Assessment Process for Companion Diagnostic Tests: The Companion test Assessment Tool (CAT). Journal of Managed Care & Specialty Pharmacy. 21: 700-12. PMID 26233542  1
2015 Gallego CJ, Shirts BH, Bennette CS, Guzauskas G, Amendola LM, Horike-Pyne M, Hisama FM, Pritchard CC, Grady WM, Burke W, Jarvik GP, Veenstra DL. Next-Generation Sequencing Panels for the Diagnosis of Colorectal Cancer and Polyposis Syndromes: A Cost-Effectiveness Analysis. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 33: 2084-91. PMID 25940718 DOI: 10.1200/JCO.2014.59.3665  1
2015 Roth JA, Bradley K, Thummel KE, Veenstra DL, Boudreau D. Alcohol misuse, genetics, and major bleeding among warfarin therapy patients in a community setting. Pharmacoepidemiology and Drug Safety. 24: 619-27. PMID 25858232 DOI: 10.1002/pds.3769  1
2015 Bennette CS, Burke W, Jarvik GP, Veenstra DL. Response to Phillips et al. Genetics in Medicine : Official Journal of the American College of Medical Genetics. 17: 315. PMID 25835196 DOI: 10.1038/gim.2015.11  1
2015 Sullivan SD, Yeung K, Vogeler C, Ramsey SD, Wong E, Murphy CO, Danielson D, Veenstra DL, Garrison LP, Burke W, Watkins JB. Design, implementation, and first-year outcomes of a value-based drug formulary. Journal of Managed Care & Specialty Pharmacy. 21: 269-75. PMID 25803760  1
2015 Bennette CS, Gallego CJ, Burke W, Jarvik GP, Veenstra DL. The cost-effectiveness of returning incidental findings from next-generation genomic sequencing. Genetics in Medicine : Official Journal of the American College of Medical Genetics. 17: 587-95. PMID 25394171 DOI: 10.1038/gim.2014.156  1
2015 Ramsey SD, Henry NL, Gralow JR, Mirick DK, Barlow W, Etzioni R, Mummy D, Thariani R, Veenstra DL. Tumor marker usage and medical care costs among older early-stage breast cancer survivors. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 33: 149-55. PMID 25332254 DOI: 10.1200/JCO.2014.55.5409  1
2015 Williams JK, Cashion AK, Veenstra DL. Challenges in evaluating next-generation sequence data for clinical decisions. Nursing Outlook. 63: 48-50. PMID 25261386 DOI: 10.1016/j.outlook.2014.08.007  1
2014 Boudreau DM, Guzauskas GF, Chen E, Lalla D, Tayama D, Fagan SC, Veenstra DL. Cost-effectiveness of recombinant tissue-type plasminogen activator within 3 hours of acute ischemic stroke: current evidence. Stroke; a Journal of Cerebral Circulation. 45: 3032-9. PMID 25190439 DOI: 10.1161/STROKEAHA.114.005852  1
2014 Gallego CJ, Bennette CS, Heagerty P, Comstock B, Horike-Pyne M, Hisama F, Amendola LM, Bennett RL, Dorschner MO, Tarczy-Hornoch P, Grady WM, Fullerton SM, Trinidad SB, Regier DA, Nickerson DA, ... ... Veenstra DL, et al. Comparative effectiveness of next generation genomic sequencing for disease diagnosis: design of a randomized controlled trial in patients with colorectal cancer/polyposis syndromes. Contemporary Clinical Trials. 39: 1-8. PMID 24997220 DOI: 10.1016/j.cct.2014.06.016  1
2014 Khandelwal N, Hough CL, Bansal A, Veenstra DL, Treggiari MM. Long-term survival in patients with severe acute respiratory distress syndrome and rescue therapies for refractory hypoxemia*. Critical Care Medicine. 42: 1610-8. PMID 24732240 DOI: 10.1097/CCM.0000000000000322  1
2014 Bajaj PS, Veenstra DL, Goertz HP, Carlson JJ. Targeted erlotinib for first-line treatment of advanced non-small cell lung cancer: a budget impact analysis. Journal of Medical Economics. 17: 538-46. PMID 24716717 DOI: 10.3111/13696998.2014.912987  1
2014 Roth JA, Boudreau D, Fujii MM, Farin FM, Rettie AE, Thummel KE, Veenstra DL. Genetic risk factors for major bleeding in patients treated with warfarin in a community setting. Clinical Pharmacology and Therapeutics. 95: 636-43. PMID 24503627 DOI: 10.1038/clpt.2014.26  1
2014 Calonge N, Klein RD, Berg AO, Berg JS, Armstrong K, Botkin J, Campos-Outcalt D, Djulbegovic B, Fisher NL, Ganiats TG, Haddow JE, Hayes M, Janssens ACJW, Kaye C, Lyman DO, ... ... Veenstra DL, et al. The EGAPP initiative: Lessons learned Genetics in Medicine. 16: 217-224. PMID 23928914 DOI: 10.1038/gim.2013.110  1
2013 Thariani R, Henry NL, Ramsey SD, Blough DK, Barlow B, Gralow JR, Veenstra DL. Is a comparative clinical trial for breast cancer tumor markers to monitor disease recurrence warranted? A value of information analysis. Journal of Comparative Effectiveness Research. 2: 325-34. PMID 24236631 DOI: 10.2217/cer.13.15  1
2013 Bates SM, Greer IA, Middeldorp S, Veenstra DL, Prabulos AM, Vandvik PO. Recommendations for prophylaxis of pregnancy-related venous thromboembolism in carriers of inherited thrombophilia. Comment on the 2012 ACCP guidelines: A rebuttal Journal of Thrombosis and Haemostasis. 11: 1782-1784. PMID 23819793 DOI: 10.1111/jth.12347  1
2013 Verhoef TI, Redekop WK, Veenstra DL, Thariani R, Beltman PA, van Schie RM, de Boer A, Maitland-van der Zee AH. Cost-effectiveness of pharmacogenetic-guided dosing of phenprocoumon in atrial fibrillation. Pharmacogenomics. 14: 869-83. PMID 23746182 DOI: 10.2217/pgs.13.74  1
2013 Bennette CS, Trinidad SB, Fullerton SM, Patrick D, Amendola L, Burke W, Hisama FM, Jarvik GP, Regier DA, Veenstra DL. Return of incidental findings in genomic medicine: measuring what patients value--development of an instrument to measure preferences for information from next-generation testing (IMPRINT). Genetics in Medicine : Official Journal of the American College of Medical Genetics. 15: 873-81. PMID 23722871 DOI: 10.1038/gim.2013.63  1
2013 Carlson JJ, Thariani R, Roth J, Gralow J, Henry NL, Esmail L, Deverka P, Ramsey SD, Baker L, Veenstra DL. Value-of-information analysis within a stakeholder-driven research prioritization process in a US setting: an application in cancer genomics. Medical Decision Making : An International Journal of the Society For Medical Decision Making. 33: 463-71. PMID 23635833 DOI: 10.1177/0272989X13484388  1
2013 Feero WG, Wicklund C, Veenstra DL. The economics of genomic medicine: insights from the IOM Roundtable on Translating Genomic-Based Research for Health. Jama. 309: 1235-6. PMID 23532238 DOI: 10.1001/jama.2013.113  1
2013 Spackman DE, Kadiyala S, Neumann PJ, Veenstra DL, Sullivan SD. The validity of dependence as a health outcome measure in Alzheimer's disease. American Journal of Alzheimer's Disease and Other Dementias. 28: 245-52. PMID 23512996 DOI: 10.1177/1533317513481092  1
2013 Calonge N, Fisher NL, Berg AO, Campos-Outcalt D, Djulbegovic B, Ganiats TG, Haddow JE, Klein RD, Lyman DO, Offit K, Pauker SG, Piper M, Richards CS, Strickland OL, Tunis SR, ... Veenstra DL, et al. Recommendations from the EGAPP Working Group: Can testing of tumor tissue for mutations in EGFR pathway downstream effector genes in patients with metastatic colorectal cancer improve health outcomes by guiding decisions regarding anti-EGFR therapy? Genetics in Medicine. 15: 517-527. PMID 23429431 DOI: 10.1038/gim.2012.184  1
2013 Bajaj PS, Veenstra DL. A risk-benefit analysis of factor V Leiden testing to improve pregnancy outcomes: a case study of the capabilities of decision modeling in genomics. Genetics in Medicine : Official Journal of the American College of Medical Genetics. 15: 374-81. PMID 23138100 DOI: 10.1038/gim.2012.139  1
2013 Esmail LC, Roth J, Rangarao S, Carlson JJ, Thariani R, Ramsey SD, Veenstra DL, Deverka P. Getting our priorities straight: a novel framework for stakeholder-informed prioritization of cancer genomics research. Genetics in Medicine : Official Journal of the American College of Medical Genetics. 15: 115-22. PMID 23037935 DOI: 10.1038/gim.2012.103  1
2013 Veenstra DL, Piper M, Haddow JE, Pauker SG, Klein R, Richards CS, Tunis SR, Djulbegovic B, Marrone M, Lin JS, Berg AO, Calonge N. Improving the efficiency and relevance of evidence-based recommendations in the era of whole-genome sequencing: an EGAPP methods update. Genetics in Medicine : Official Journal of the American College of Medical Genetics. 15: 14-24. PMID 22955111 DOI: 10.1038/gim.2012.106  1
2013 Guzauskas GF, Garrison LP, Stock J, Au S, Doyle DL, Veenstra DL. Stakeholder perspectives on decision-analytic modeling frameworks to assess genetic services policy. Genetics in Medicine : Official Journal of the American College of Medical Genetics. 15: 84-7. PMID 22836698 DOI: 10.1038/gim.2012.92  1
2013 Boudreau DM, Guzauskas G, Villa KF, Fagan SC, Veenstra DL. A model of cost-effectiveness of tissue plasminogen activator in patient subgroups 3 to 4.5 hours after onset of acute ischemic stroke. Annals of Emergency Medicine. 61: 46-55. PMID 22633340 DOI: 10.1016/j.annemergmed.2012.04.020  1
2013 Veenstra DL. Economic Issues and Genomic Medicine Genomic and Personalized Medicine. 1: 440-446. DOI: 10.1016/B978-0-12-382227-7.00039-2  1
2012 Deverka PA, Lavallee DC, Desai PJ, Armstrong J, Gorman M, Hole-Curry L, O'Leary J, Ruffner BW, Watkins J, Veenstra DL, Baker LH, Unger JM, Ramsey SD. Facilitating comparative effectiveness research in cancer genomics: evaluating stakeholder perceptions of the engagement process. Journal of Comparative Effectiveness Research. 1: 359-70. PMID 23459832 DOI: 10.2217/cer.12.36  1
2012 Dale CR, Madtes DK, Fan VS, Gorden JA, Veenstra DL. Navigational bronchoscopy with biopsy versus computed tomography-guided biopsy for the diagnosis of a solitary pulmonary nodule: a cost-consequences analysis. Journal of Bronchology & Interventional Pulmonology. 19: 294-303. PMID 23207529 DOI: 10.1097/LBR.0b013e318272157d  1
2012 Wong WB, Ramsey SD, Barlow WE, Garrison LP, Veenstra DL. The value of comparative effectiveness research: projected return on investment of the RxPONDER trial (SWOG S1007). Contemporary Clinical Trials. 33: 1117-23. PMID 22981891 DOI: 10.1016/j.cct.2012.08.006  1
2012 Deverka PA, Lavallee DC, Desai PJ, Esmail LC, Ramsey SD, Veenstra DL, Tunis SR. Stakeholder participation in comparative effectiveness research: defining a framework for effective engagement. Journal of Comparative Effectiveness Research. 1: 181-194. PMID 22707880 DOI: 10.2217/cer.12.7  1
2012 Guzauskas GF, Boudreau DM, Villa KF, Levine SR, Veenstra DL. The cost-effectiveness of primary stroke centers for acute stroke care. Stroke; a Journal of Cerebral Circulation. 43: 1617-23. PMID 22535277 DOI: 10.1161/STROKEAHA.111.648238  1
2012 Goddard KA, Knaus WA, Whitlock E, Lyman GH, Feigelson HS, Schully SD, Ramsey S, Tunis S, Freedman AN, Khoury MJ, Veenstra DL. Building the evidence base for decision making in cancer genomic medicine using comparative effectiveness research. Genetics in Medicine : Official Journal of the American College of Medical Genetics. 14: 633-42. PMID 22516979 DOI: 10.1038/gim.2012.16  1
2012 Guzauskas GF, Hughes DA, Bradley SM, Veenstra DL. A risk-benefit assessment of prasugrel, clopidogrel, and genotype-guided therapy in patients undergoing percutaneous coronary intervention. Clinical Pharmacology and Therapeutics. 91: 829-37. PMID 22453194 DOI: 10.1038/clpt.2011.303  1
2012 Cheng MM, Ramsey SD, Devine EB, Garrison LP, Bresnahan BW, Veenstra DL. Systematic review of comparative effectiveness data for oncology orphan drugs. The American Journal of Managed Care. 18: 47-62. PMID 22435748  1
2012 Thariani R, Veenstra DL, Carlson JJ, Garrison LP, Ramsey S. Paying for personalized care: cancer biomarkers and comparative effectiveness. Molecular Oncology. 6: 260-6. PMID 22429896 DOI: 10.1016/j.molonc.2012.02.006  1
2012 Cheng MM, Goulart B, Veenstra DL, Blough DK, Devine EB. A network meta-analysis of therapies for previously untreated chronic lymphocytic leukemia. Cancer Treatment Reviews. 38: 1004-11. PMID 22405931 DOI: 10.1016/j.ctrv.2012.02.006  1
2012 Babigumira JB, Stergachis A, Veenstra DL, Gardner JS, Ngonzi J, Mukasa-Kivunike P, Garrison LP. Potential cost-effectiveness of universal access to modern contraceptives in Uganda. Plos One. 7: e30735. PMID 22363480 DOI: 10.1371/journal.pone.0030735  1
2012 Bates SM, Greer IA, Middeldorp S, Veenstra DL, Prabulos AM, Vandvik PO. VTE, thrombophilia, antithrombotic therapy, and pregnancy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 141: e691S-736S. PMID 22315276 DOI: 10.1378/chest.11-2300  1
2012 Holbrook A, Schulman S, Witt DM, Vandvik PO, Fish J, Kovacs MJ, Svensson PJ, Veenstra DL, Crowther M, Guyatt GH. Evidence-based management of anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 141: e152S-84S. PMID 22315259 DOI: 10.1378/chest.11-2295  1
2012 Thariani R, Wong W, Carlson JJ, Garrison L, Ramsey S, Deverka PA, Esmail L, Rangarao S, Hoban CJ, Baker LH, Veenstra DL. Prioritization in comparative effectiveness research: the CANCERGEN Experience. Medical Care. 50: 388-93. PMID 22274803 DOI: 10.1097/MLR.0b013e3182422a3b  1
2012 Branch KR, Bresnahan BW, Veenstra DL, Shuman WP, Weintraub WS, Busey JM, Elliott DJ, Mitsumori LM, Strote J, Jobe K, Dubinsky T, Caldwell JH. Economic outcome of cardiac CT-based evaluation and standard of care for suspected acute coronary syndrome in the emergency department: a decision analytic model. Academic Radiology. 19: 265-73. PMID 22209422 DOI: 10.1016/j.acra.2011.10.029  1
2012 Spackman DE, Kadiyala S, Neumann PJ, Veenstra DL, Sullivan SD. Measuring Alzheimer disease progression with transition probabilities: estimates from NACC-UDS. Current Alzheimer Research. 9: 1050-8. PMID 22175655 DOI: 10.2174/156720512803569046  1
2012 Blondon M, Righini M, Bounameaux H, Veenstra DL. Fondaparinux for isolated superficial vein thrombosis of the legs: a cost-effectiveness analysis. Chest. 141: 321-9. PMID 21757569 DOI: 10.1378/chest.11-0625  1
2011 Babigumira JB, Stergachis A, Veenstra DL, Gardner JS, Ngonzi J, Mukasa-Kivunike P, Garrison LP. Estimating the costs of induced abortion in Uganda: a model-based analysis. Bmc Public Health. 11: 904. PMID 22145859 DOI: 10.1186/1471-2458-11-904  1
2011 Beitelshees AL, Veenstra DL. Evolving research and stakeholder perspectives on pharmacogenomics. Jama. 306: 1252-3. PMID 21934059 DOI: 10.1001/jama.2011.1343  1
2011 Garrison LP, Bauch CT, Bresnahan BW, Hazlet TK, Kadiyala S, Veenstra DL. Using cost-effectiveness analysis to support research and development portfolio prioritization for product innovations in measles vaccination. The Journal of Infectious Diseases. 204: S124-32. PMID 21666153 DOI: 10.1093/infdis/jir114  1
2011 Bloudek LM, Spackman DE, Veenstra DL, Sullivan SD. CDR state transition probabilities in Alzheimer's disease with and without cholinesterase inhibitor intervention in an observational cohort. Journal of Alzheimer's Disease : Jad. 24: 599-607. PMID 21297268 DOI: 10.3233/JAD-2011-101758  1
2011 Cross JT, Veenstra DL, Gardner JS, Garrison LP. Can modeling of health outcomes facilitate regulatory decision making? The benefit-risk tradeoff for rosiglitazone in 1999 vs. 2007. Clinical Pharmacology and Therapeutics. 89: 429-36. PMID 21289618 DOI: 10.1038/clpt.2010.350  1
2011 Carlson JJ, Wong WB, Veenstra DL, Reyes C. Budget impact of erlotinib for maintenance therapy in advanced non-small cell lung cancer. Journal of Medical Economics. 14: 159-66. PMID 21288059 DOI: 10.3111/13696998.2011.557457  1
2011 Roth JA, Garrison LP, Burke W, Ramsey SD, Carlson R, Veenstra DL. Stakeholder perspectives on a risk-benefit framework for genetic testing. Public Health Genomics. 14: 59-67. PMID 20407215 DOI: 10.1159/000290452  1
2010 Overby CL, Tarczy-Hornoch P, Hoath JI, Kalet IJ, Veenstra DL. Feasibility of incorporating genomic knowledge into electronic medical records for pharmacogenomic clinical decision support. Bmc Bioinformatics. 11: S10. PMID 21044357 DOI: 10.1186/1471-2105-11-S9-S10  1
2010 Wong WB, Carlson JJ, Thariani R, Veenstra DL. Cost effectiveness of pharmacogenomics: a critical and systematic review. Pharmacoeconomics. 28: 1001-13. PMID 20936884 DOI: 10.2165/11537410-000000000-00000  1
2010 Veenstra DL, Roth JA, Garrison LP, Ramsey SD, Burke W. A formal risk-benefit framework for genomic tests: facilitating the appropriate translation of genomics into clinical practice. Genetics in Medicine : Official Journal of the American College of Medical Genetics. 12: 686-93. PMID 20808229 DOI: 10.1097/GIM.0b013e3181eff533  1
2010 Cheng MM, Alfonso R, Best JH, Garrison LP, Bruhn D, Veenstra DL. The economic value of reducing medication dosing frequency with drug delivery technologies: an evidence assessment. Journal of Medical Economics. 13: 193-202. PMID 20334490 DOI: 10.3111/13696991003757500  1
2010 Carlson JJ, Sullivan SD, Garrison LP, Neumann PJ, Veenstra DL. Linking payment to health outcomes: a taxonomy and examination of performance-based reimbursement schemes between healthcare payers and manufacturers. Health Policy (Amsterdam, Netherlands). 96: 179-90. PMID 20226559 DOI: 10.1016/j.healthpol.2010.02.005  1
2010 Conti R, Veenstra DL, Armstrong K, Lesko LJ, Grosse SD. Personalized medicine and genomics: challenges and opportunities in assessing effectiveness, cost-effectiveness, and future research priorities. Medical Decision Making : An International Journal of the Society For Medical Decision Making. 30: 328-40. PMID 20086232 DOI: 10.1177/0272989X09347014  1
2010 Best JH, Garrison LP, Hollingworth W, Ramsey SD, Veenstra DL. Preference values associated with stage III colon cancer and adjuvant chemotherapy. Quality of Life Research : An International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation. 19: 391-400. PMID 20084462 DOI: 10.1007/s11136-010-9589-5  1
2010 Meckley LM, Gudgeon JM, Anderson JL, Williams MS, Veenstra DL. A policy model to evaluate the benefits, risks and costs of warfarin pharmacogenomic testing. Pharmacoeconomics. 28: 61-74. PMID 20014877 DOI: 10.2165/11318240-000000000-00000  1
2010 Limdi NA, Veenstra DL. Expectations, validity, and reality in pharmacogenetics. Journal of Clinical Epidemiology. 63: 960-9. PMID 19995676 DOI: 10.1016/j.jclinepi.2009.09.006  1
2010 Veenstra DL. The role of epidemiology in assessing the potential clinical impact of pharmacogenomics Human Genome Epidemiology: Building the Evidence For Using Genetic Information to Improve Health and Prevent Disease: Second Edition. DOI: 10.1093/acprof:oso/9780195398441.003.0027  1
2010 Veenstra DL, Garrison LP, Ramsey SD. Economic Issues and Genomic Medicine Essentials of Genomic and Personalized Medicine. 233-244. DOI: 10.1016/B978-0-12-374934-5.00020-9  1
2009 Bradley SM, Levy WC, Veenstra DL. Cost-consequences of ultrafiltration for acute heart failure: a decision model analysis. Circulation. Cardiovascular Quality and Outcomes. 2: 566-73. PMID 20031894 DOI: 10.1161/CIRCOUTCOMES.109.853556  1
2009 Salinger DH, Shen DD, Thummel K, Wittkowsky AK, Vicini P, Veenstra DL. Pharmacogenomic trial design: use of a PK/PD model to explore warfarin dosing interventions through clinical trial simulation. Pharmacogenetics and Genomics. 19: 965-71. PMID 19881396 DOI: 10.1097/FPC.0b013e3283333b80  1
2009 Garrison LP, Veenstra DL. The economic value of innovative treatments over the product life cycle: the case of targeted trastuzumab therapy for breast cancer. Value in Health : the Journal of the International Society For Pharmacoeconomics and Outcomes Research. 12: 1118-23. PMID 19624617 DOI: 10.1111/j.1524-4733.2009.00572.x  1
2009 Carlson JJ, Kowdley KV, Sullivan SD, Ramsey SD, Veenstra DL. An evaluation of the potential cost-effectiveness of non-invasive testing strategies in the diagnosis of significant liver fibrosis. Journal of Gastroenterology and Hepatology. 24: 786-91. PMID 19457153 DOI: 10.1111/j.1440-1746.2009.05778.x  1
2009 Carlson JJ, Garrison LP, Ramsey SD, Veenstra DL. Epidermal growth factor receptor genomic variation in NSCLC patients receiving tyrosine kinase inhibitor therapy: a systematic review and meta-analysis. Journal of Cancer Research and Clinical Oncology. 135: 1483-93. PMID 19430813 DOI: 10.1007/s00432-009-0595-3  1
2009 Cheng MM, Lu B, Hu SS, Marelli C, Higashi MK, Patel PA, Li J, Veenstra DL. Optimizing CAD diagnosis in China with CT angiography. Journal of Cardiovascular Computed Tomography. 3: 153-8. PMID 19394919 DOI: 10.1016/j.jcct.2009.03.005  1
2009 Carlson JJ, Garrison LP, Ramsey SD, Veenstra DL. The potential clinical and economic outcomes of pharmacogenomic approaches to EGFR-tyrosine kinase inhibitor therapy in non-small-cell lung cancer. Value in Health : the Journal of the International Society For Pharmacoeconomics and Outcomes Research. 12: 20-7. PMID 18647257 DOI: 10.1111/j.1524-4733.2008.00415.x  1
2008 Spackman DE, Veenstra DL. A cost-effectiveness analysis of currently approved treatments for HBeAg-positive chronic hepatitis B. Pharmacoeconomics. 26: 937-49. PMID 18850763 DOI: 10.2165/00019053-200826110-00006  1
2008 Limdi NA, Veenstra DL. Warfarin pharmacogenetics. Pharmacotherapy. 28: 1084-97. PMID 18752379 DOI: 10.1592/phco.28.9.1084  1
2008 Meckley LM, Wittkowsky AK, Rieder MJ, Rettie AE, Veenstra DL. An analysis of the relative effects of VKORC1 and CYP2C9 variants on anticoagulation related outcomes in warfarin-treated patients Thrombosis and Haemostasis. 100: 229-239. PMID 18690342 DOI: 10.1160/TH07-09-0552  1
2008 Cooper GM, Johnson JA, Langaee TY, Feng H, Stanaway IB, Schwarz UI, Ritchie MD, Stein CM, Roden DM, Smith JD, Veenstra DL, Rettie AE, Rieder MJ. A genome-wide scan for common genetic variants with a large influence on warfarin maintenance dose. Blood. 112: 1022-7. PMID 18535201 DOI: 10.1182/blood-2008-01-134247  1
2008 Carlson JJ, Veenstra DL, Ramsey SD. Pharmacoeconomic evaluations in the treatment of non-small cell lung cancer. Drugs. 68: 1105-13. PMID 18484801 DOI: 10.2165/00003495-200868080-00007  1
2008 Garrison LP, Carlson RJ, Carlson JJ, Kuszler PC, Meckley LM, Veenstra DL. A review of public policy issues in promoting the development and commercialization of pharmacogenomic applications: challenges and implications. Drug Metabolism Reviews. 40: 377-401. PMID 18464050 DOI: 10.1080/03602530801952500  1
2008 Veenstra DL, Sullivan SD, Lai MY, Lee CM, Tsai CM, Patel KK. HBeAg-negative chronic hepatitis B: cost-effectiveness of peginterferon alfa-2a compared to lamivudine in Taiwan. Value in Health : the Journal of the International Society For Pharmacoeconomics and Outcomes Research. 11: 131-8. PMID 18380625 DOI: 10.1111/j.1524-4733.2007.00221.x  1
2008 Jaja C, Burke W, Thummel K, Edwards K, Veenstra DL. Cytochrome p450 enzyme polymorphism frequency in indigenous and native american populations: a systematic review. Community Genetics. 11: 141-9. PMID 18376110 DOI: 10.1159/000113876  1
2008 Gage BF, Eby C, Johnson JA, Deych E, Rieder MJ, Ridker PM, Milligan PE, Grice G, Lenzini P, Rettie AE, Aquilante CL, Grosso L, Marsh S, Langaee T, Farnett LE, ... ... Veenstra DL, et al. Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin. Clinical Pharmacology and Therapeutics. 84: 326-31. PMID 18305455 DOI: 10.1038/clpt.2008.10  1
2008 Carlson JJ, Reyes C, Oestreicher N, Lubeck D, Ramsey SD, Veenstra DL. Comparative clinical and economic outcomes of treatments for refractory non-small cell lung cancer (NSCLC) Lung Cancer. 61: 405-415. PMID 18295368 DOI: 10.1016/j.lungcan.2007.12.023  1
2008 Strassels SA, Blough DK, Veenstra DL, Hazlet TK, Sullivan SD. Clinical and demographic characteristics help explain variations in pain at the end of life. Journal of Pain and Symptom Management. 35: 10-9. PMID 17959344 DOI: 10.1016/j.jpainsymman.2007.02.036  1
2008 Henrikson NB, Burke W, Veenstra DL. Ancillary risk information and pharmacogenetic tests: Social and policy implications Pharmacogenomics Journal. 8: 85-89. PMID 17486108 DOI: 10.1038/sj.tpj.6500457  1
2008 Veenstra DL, Spackman DE, Bisceglie A, Kowdley KV, Gish RG. Evaluating anti-viral drug selection and treatment duration in HBeAg-negative chronic hepatitis B: A cost-effectiveness analysis (Alimentary Pharmacology and Therapeutic (2008) 27, (1240-1252)) Alimentary Pharmacology and Therapeutics. 28: 166. DOI: 10.1111/j.1365-2036.2008.03743.x  1
2008 Gage BF, Eby C, Johnson JA, Deych E, Rieder MJ, Ridker PM, Milligan PE, Grice G, Lenzini P, Rettie AE, Aquilante CL, Grosso L, Marsh S, Langaee T, Farnett LE, ... ... Veenstra DL, et al. Corrigendum: Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin (Clinical Pharmacology Therapeutics (2008) 84, (326-331) DOI: 10.1038/clpt.2008.10) Clinical Pharmacology and Therapeutics. 84: 430. DOI: 10.1038/clpt.2008.112  1
2007 Veenstra DL, Harris J, Gibson RL, Rosenfeld M, Burke W, Watts C. Pharmacogenomic testing to prevent aminoglycoside-induced hearing loss in cystic fibrosis patients: potential impact on clinical, patient, and economic outcomes. Genetics in Medicine : Official Journal of the American College of Medical Genetics. 9: 695-704. PMID 18073583 DOI: 10.1097/GIM.0b013e318156dd07  1
2007 Veenstra DL, Sullivan SD, Clarke L, Iloeje UH, Tafesse E, Di Bisceglie A, Kowdley KV, Gish RG. Cost effectiveness of entecavir versus lamivudine with adefovir salvage in HBeAg-positive chronic hepatitis B. Pharmacoeconomics. 25: 963-77. PMID 17960954  1
2007 Sullivan SD, Veenstra DL, Chen PJ, Chang TT, Chuang WL, Tsai C, Patel K. Cost-effectiveness of peginterferon alpha-2a compared to lamivudine treatment in patients with hepatitis B e antigen positive chronic hepatitis B in Taiwan. Journal of Gastroenterology and Hepatology. 22: 1494-9. PMID 17716353 DOI: 10.1111/j.1440-1746.2006.04539.x  0.32
2007 Veenstra DL. The cost-effectiveness of warfarin pharmacogenomics [2] Journal of Thrombosis and Haemostasis. 5: 1974-1975. PMID 17650084 DOI: 10.1111/j.1538-7836.2007.02699.x  1
2007 Veenstra DL, Sullivan SD, Dusheiko GM, Jacobs M, Aledort JE, Lewis G, Patel KK. Cost-effectiveness of peginterferon alpha-2a compared with lamivudine treatment in patients with HBe-antigen-positive chronic hepatitis B in the United Kingdom. European Journal of Gastroenterology & Hepatology. 19: 631-8. PMID 17625431 DOI: 10.1097/MEG.0b013e3281108079  1
2006 Strassels SA, Blough DK, Hazlet TK, Veenstra DL, Sullivan SD. Pain, demographics, and clinical characteristics in persons who received hospice care in the United States. Journal of Pain and Symptom Management. 32: 519-31. PMID 17157754 DOI: 10.1016/j.jpainsymman.2006.06.005  1
2006 Ramsey SD, Veenstra DL, Garrison LP, Carlson R, Billings P, Carlson J, Sullivan SD. Toward evidence-based assessment for coverage and reimbursement of laboratory-based diagnostic and genetic tests. The American Journal of Managed Care. 12: 197-202. PMID 16610921  1
2006 Meckley LM, Veenstra DL. Screening for the alpha-adducin Gly460Trp variant in hypertensive patients: a cost-effectiveness analysis. Pharmacogenetics and Genomics. 16: 139-47. PMID 16424826  1
2006 Van Der Palen J, Monninkhof E, Van Der Valk P, Sullivan SD, Veenstra DL. Cost effectiveness of inhaled steroid withdrawal in outpatients with chronic obstructive pulmonary disease Thorax. 61: 29-33. PMID 16244087 DOI: 10.1136/thx.2005.044578  1
2005 Carlson JJ, Henrikson NB, Veenstra DL, Ramsey SD. Economic analyses of human genetics services: a systematic review. Genetics in Medicine : Official Journal of the American College of Medical Genetics. 7: 519-23. PMID 16247290 DOI: 10.1097/01.GIM.0000182467.79495.e2  1
2005 Oestreicher N, Ramsey SD, McCune JS, Linden HM, Veenstra DL. The cost of adjuvant chemotherapy in patients with early-stage breast carcinoma. Cancer. 104: 2054-62. PMID 16216002 DOI: 10.1002/cncr.21464  1
2005 Veenstra DL, You JHS, Rieder MJ, Farin FM, Wilkerson HW, Blough DK, Cheng G, Rettie AE. Association of Vitamin K epoxide reductase complex 1 (VKORC1) variants with warfarin dose in a Hong Kong Chinese patient population Pharmacogenetics and Genomics. 15: 687-691. PMID 16141794  1
2005 Oestreicher N, Ramsey SD, Linden HM, McCune JS, van't Veer LJ, Burke W, Veenstra DL. Gene expression profiling and breast cancer care: what are the potential benefits and policy implications? Genetics in Medicine : Official Journal of the American College of Medical Genetics. 7: 380-9. PMID 16024969 DOI: 10.1097/01.GIM.0000170776.31248.75  1
2005 Tai G, Farin F, Rieder MJ, Dreisbach AW, Veenstra DL, Verlinde CL, Rettie AE. In-vitro and in-vivo effects of the CYP2C9*11 polymorphism on warfarin metabolism and dose. Pharmacogenetics and Genomics. 15: 475-81. PMID 15970795  0.32
2005 Rieder MJ, Reiner AP, Gage BF, Nickerson DA, Eby CS, McLeod HL, Blough DK, Thummel KE, Veenstra DL, Rettie AE. Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. The New England Journal of Medicine. 352: 2285-93. PMID 15930419 DOI: 10.1056/NEJMoa044503  1
2005 Veenstra DL, Blough DK, Higashi MK, Farin FM, Srinouanprachan S, Rieder MJ, Rettie AE. CYP2C9 haplotype structure in European American warfarin patients and association with clinical outcomes. Clinical Pharmacology and Therapeutics. 77: 353-64. PMID 15900281 DOI: 10.1016/j.clpt.2005.01.019  1
2005 Davis GE, Schwartz SR, Veenstra DL, Yueh B. Cost comparison of surgery vs organ preservation for laryngeal cancer. Archives of Otolaryngology--Head & Neck Surgery. 131: 21-6. PMID 15655180 DOI: 10.1001/archotol.131.1.21  1
2004 Custer B, Sullivan SD, Hazlet TK, Iloeje U, Veenstra DL, Kowdley KV. Global epidemiology of hepatitis B virus. Journal of Clinical Gastroenterology. 38: S158-68. PMID 15602165  1
2004 Lee TA, Veenstra DL, Iloeje UH, Sullivan SD. Cost of chronic hepatitis B infection in the United States. Journal of Clinical Gastroenterology. 38: S144-7. PMID 15602162  1
2004 Salem L, Veenstra DL, Sullivan SD, Flum DR. The timing of elective colectomy in diverticulitis: a decision analysis. Journal of the American College of Surgeons. 199: 904-12. PMID 15555974 DOI: 10.1016/j.jamcollsurg.2004.07.029  1
2004 Hu KK, Veenstra DL, Lipsky BA, Saint S. Use of maximal sterile barriers during central venous catheter insertion: clinical and economic outcomes. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. 39: 1441-5. PMID 15546079 DOI: 10.1086/425309  1
2004 Phillips KA, Veenstra DL, Ramsey SD, Van Bebber SL, Sakowski J. Genetic testing and pharmacogenomics: issues for determining the impact to healthcare delivery and costs. The American Journal of Managed Care. 10: 425-32. PMID 15298364  1
2004 Veenstra DL. Bringing genomics to the bedside: a cost-effective pharmacogenomic test? Pharmacogenetics. 14: 333-4. PMID 15247624 DOI: 10.1097/00008571-200406000-00001  1
2004 Hu KK, Lipsky BA, Veenstra DL, Saint S. Using maximal sterile barriers to prevent central venous catheter-related infection: a systematic evidence-based review. American Journal of Infection Control. 32: 142-6. PMID 15153925 DOI: 10.1016/j.ajic.2003.10.006  1
2004 Arterburn DE, Crane PK, Veenstra DL. The efficacy and safety of sibutramine for weight loss: a systematic review. Archives of Internal Medicine. 164: 994-1003. PMID 15136309 DOI: 10.1001/archinte.164.9.994  1
2004 Maitland-van der Zee AH, Klungel OH, Stricker BH, Veenstra DL, Kastelein JJ, Hofman A, Witteman JC, Leufkens HG, van Duijn CM, de Boer A. Pharmacoeconomic evaluation of testing for angiotensin-converting enzyme genotype before starting beta-hydroxy-beta-methylglutaryl coenzyme A reductase inhibitor therapy in men. Pharmacogenetics. 14: 53-60. PMID 15128051 DOI: 10.1097/00008571-200401000-00006  1
2004 Higashi MK, Veenstra DL, Langley PC. Health economic evaluation of non-melanoma skin cancer and actinic keratosis. Pharmacoeconomics. 22: 83-94. PMID 14731050 DOI: 10.2165/00019053-200422020-00002  1
2003 Patel KK, Veenstra DL, Patrick DL. A review of selected patient-generated outcome measures and their application in clinical trials. Value in Health : the Journal of the International Society For Pharmacoeconomics and Outcomes Research. 6: 595-603. PMID 14627066 DOI: 10.1046/j.1524-4733.2003.65236.x  1
2003 Chaiyakunapruk N, Veenstra DL, Lipsky BA, Sullivan SD, Saint S. Vascular catheter site care: the clinical and economic benefits of chlorhexidine gluconate compared with povidone iodine. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. 37: 764-71. PMID 12955636 DOI: 10.1086/377265  1
2003 Higashi MK, Veenstra DL. Managed care in the genomics era: assessing the cost effectiveness of genetic tests. The American Journal of Managed Care. 9: 493-500. PMID 12866628  1
2003 Reed SD, Dillingham PW, Briggs AH, Veenstra DL, Sullivan SD. A Bayesian approach to aid in formulary decision making: incorporating institution-specific cost-effectiveness data with clinical trial results. Medical Decision Making : An International Journal of the Society For Medical Decision Making. 23: 252-64. PMID 12809323 DOI: 10.1177/0272989X03023003007  1
2003 Gray DT, Veenstra DL. Comparative economic analyses of minimally invasive direct coronary artery bypass surgery. The Journal of Thoracic and Cardiovascular Surgery. 125: 618-24. PMID 12658204 DOI: 10.1067/mtc.2003.14  1
2003 Flum DR, Flowers C, Veenstra DL. A cost-effectiveness analysis of intraoperative cholangiography in the prevention of bile duct injury during laparoscopic cholecystectomy. Journal of the American College of Surgeons. 196: 385-93. PMID 12648690 DOI: 10.1016/S1072-7515(02)01806-9  1
2003 Rettie AE, Tai G, Veenstra DL, Farin FM, Srinouanprachan S, Lin YS, Thummel KE, Hines RN. CYP2C9 exon 4 mutations and warfarin dose phenotype in Asians. Blood. 101: 2896-7. PMID 12642346 DOI: 10.1182/blood-2002-11-3452  1
2003 Ginocchio RH, Veenstra DL, Connell FA, Marrazzo JM. The clinical and economic consequences of screening young men for genital chlamydial infection. Sexually Transmitted Diseases. 30: 99-106. PMID 12567164 DOI: 10.1097/00007435-200302000-00001  1
2003 Marciante KD, Veenstra DL, Lipsky BA, Saint S. Which antimicrobial impregnated central venous catheter should we use? Modeling the costs and outcomes of antimicrobial catheter use. American Journal of Infection Control. 31: 1-8. PMID 12548250 DOI: 10.1067/mic.2003.35  1
2003 Rulyak SJ, Kimmey MB, Veenstra DL, Brentnall TA. Cost-effectiveness of pancreatic cancer screening in familial pancreatic cancer kindreds. Gastrointestinal Endoscopy. 57: 23-9. PMID 12518126 DOI: 10.1067/mge.2003.28  1
2002 Higashi MK, Veenstra DL, del Aguila M, Hujoel P. The cost-effectiveness of interleukin-1 genetic testing for periodontal disease. Journal of Periodontology. 73: 1474-84. PMID 12546098 DOI: 10.1902/jop.2002.73.12.1474  1
2002 Sullivan SD, Lew DP, Devine EB, Hakim Z, Reiber GE, Veenstra DL. Health state preference assessment in diabetic peripheral neuropathy. Pharmacoeconomics. 20: 1079-89. PMID 12456202 DOI: 10.2165/00019053-200220150-00004  1
2002 Chaiyakunapruk N, Veenstra DL, Lipsky BA, Saint S. Chlorhexidine compared with povidone-iodine solution for vascular catheter-site care: a meta-analysis. Annals of Internal Medicine. 136: 792-801. PMID 12044127  1
2002 Veenstra DL, Ramsey SD, Sullivan SD. A guideline for the use of pharmacoeconomic models of diabetes treatment in the US managed-care environment. Pharmacoeconomics. 20: 21-30. PMID 12036381  1
2002 Kurre HA, Ettinger AG, Veenstra DL, Gaynon PS, Franklin J, Sencer SF, Reaman GH, Lange BJ, Holcenberg JS. A pharmacoeconomic analysis of pegaspargase versus native Escherichia coli L-asparaginase for the treatment of children with standard-risk, acute lymphoblastic leukemia: the Children's Cancer Group study (CCG-1962). Journal of Pediatric Hematology/Oncology. 24: 175-81. PMID 11990302 DOI: 10.1097/00043426-200203000-00004  1
2002 Klungel OH, Heckbert SR, de Boer A, Leufkens HG, Sullivan SD, Fishman PA, Veenstra DL, Psaty BM. Lipid-lowering drug use and cardiovascular events after myocardial infarction. The Annals of Pharmacotherapy. 36: 751-7. PMID 11978147  1
2002 Higashi MK, Veenstra DL, Kondo LM, Wittkowsky AK, Srinouanprachanh SL, Farin FM, Rettie AE. Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. Jama. 287: 1690-8. PMID 11926893  1
2002 Veenstra DL. The role of pharmacoeconomics in the genomics era Pharmaceutical News. 9: 21-26.  1
2001 Phillips KA, Veenstra DL, Oren E, Lee JK, Sadee W. Potential role of pharmacogenomics in reducing adverse drug reactions: A systematic review Journal of the American Medical Association. 286: 2270-2279. PMID 11710893  1
2001 Devine EB, Kowdley KV, Veenstra DL, Sullivan SD. Management strategies for ribavirin-induced hemolytic anemia in the treatment of hepatitis C: clinical and economic implications. Value in Health : the Journal of the International Society For Pharmacoeconomics and Outcomes Research. 4: 376-84. PMID 11705128 DOI: 10.1046/j.1524-4733.2001.45075.x  1
2001 Best JH, Veenstra DL, Geppert J. Trends in expenditures for Medicare liver transplant recipients. Liver Transplantation : Official Publication of the American Association For the Study of Liver Diseases and the International Liver Transplantation Society. 7: 858-62. PMID 11679983 DOI: 10.1053/jlts.2001.27868  1
2001 Marciante KD, Gardner JS, Veenstra DL, Sullivan SD. Modeling the cost and outcomes of pharmacist-prescribed emergency contraception. American Journal of Public Health. 91: 1443-5. PMID 11527778  1
2001 Lee TA, Sullivan SD, Veenstra DL, Ramsey SD, Steger PJK, Malinverni R, Pleil AM, Williamson T. Economic evaluation of systemic treatments for cytomegalovirus retinitis in patients with AIDS Pharmacoeconomics. 19: 535-550. PMID 11465299  1
2001 Malone DC, Sullivan SD, Veenstra DL. Determining unit cost values for health care resources in pharmacoeconomic studies Formulary. 36: 294-304.  1
2000 Phillips KA, Veenstra DL, Sadee W. Implications of the genetics revolution for health services research: pharmacogenomics and improvements in drug therapy. Health Services Research. 35: 128-40. PMID 16148957  1
2000 Veenstra DL, Higashi MK, Phillips KA. Assessing the cost-effectiveness of pharmacogenomics. Aaps Pharmsci. 2: E29. PMID 11741245  1
2000 Saint S, Veenstra DL, Sullivan SD, Chenoweth C, Fendrick AM. The potential clinical and economic benefits of silver alloy urinary catheters in preventing urinary tract infection Archives of Internal Medicine. 160: 2670-2675. PMID 10999983  1
2000 Saint S, Veenstra DL, Lipsky BA. The clinical and economic consequences of nosocomial central venous catheter-related infection: Are antimicrobial catheters useful? Infection Control and Hospital Epidemiology. 21: 375-380. PMID 10879567  1
2000 Schierholz J, Lefering R, Neugebauer E, Beuth J, König DP, Pulverer G. Central venous catheters and bloodstream infection. Jama. 283: 477-8; author reply . PMID 10659869  1
2000 Veenstra DL, Higashi MK, Phillips KA. Assessing the comprehensiveness of pharmacogenomics Aaps Pharmsci. 2: 1-11.  1
1999 Veenstra DL, Saint S, Sullivan SD. Cost-effectiveness of antiseptic-impregnated central venous catheters for the prevention of catheter-related bloodstream infection Journal of the American Medical Association. 282: 554-560. PMID 10450717 DOI: 10.1001/jama.282.6.554  1
1999 Saint S, Veenstra DL, Sullivan SD. The use of meta-analysis in cost-effectiveness analysis issues and recommendations Pharmacoeconomics. 15: 1-8. PMID 10345156 DOI: 10.2165/00019053-199915010-00001  1
1999 Veenstra DL, Best JH, Hornberger J, Sullivan SD, Hricik DE. Incidence and long-term cost of steroid-related side effects after renal transplantation. American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation. 33: 829-39. PMID 10213637  1
1999 Veenstra DL, Best JH, Hornberger J, Sullivan SD, Hricik DE. Incidence and cost of steroid side effects after renal transplantation. Transplantation Proceedings. 31: 301-2. PMID 10083116 DOI: 10.1016/S0041-1345(98)01635-2  1
1999 Veenstra DL, Saint S, Saha S, Lumley T, Sullivan SD. Efficacy of antiseptic-impregnated central venous catheters in preventing catheter-related bloodstream infection: A meta-analysis Journal of the American Medical Association. 281: 261-267. PMID 9918482 DOI: 10.1001/jama.281.3.261  1
1998 Wang L, Veenstra DL, Radmer RJ, Kollman PA. Can one predict protein stability? An attempt to do so for residue 133 of T4 lysozyme using a combination of free energy derivatives, PROFEC, and free energy perturbation methods. Proteins. 32: 438-58. PMID 9726415 DOI: 10.1002/(SICI)1097-0134(19980901)32:4<438::AID-PROT4>3.0.CO;2-C  1
1998 Veenstra DL, Gerig JT. Fluorine NMR studies of the human carbonic anhydrase-3,5-difluorobenzenesulfonamide complex Magnetic Resonance in Chemistry. 36: S169-S178.  1
1997 Veenstra DL, Kollman PA. Modeling protein stability: a theoretical analysis of the stability of T4 lysozyme mutants. Protein Engineering. 10: 789-807. PMID 9342145  1
1996 Sun YC, Veenstra DL, Kollman PA. Free energy calculations of the mutation of Ile96-->Ala in barnase: contributions to the difference in stability. Protein Engineering. 9: 273-81. PMID 8736494  1
1992 Mendel D, Ellman JA, Chang Z, Veenstra DL, Kollman PA, Schultz PG. Probing protein stability with unnatural amino acids. Science (New York, N.Y.). 256: 1798-802. PMID 1615324 DOI: 10.1126/science.1615324  1
1992 Jacobson AR, Sylvia LA, Veenstra DL, Gerig JT. 19F[1H] NOE determinations in surface-coil experiments Journal of Magnetic Resonance (1969). 96: 387-392. DOI: 10.1016/0022-2364(92)90092-L  1
Show low-probability matches.